Sen. Charles Grassley is questioning Amgen Inc. regarding allegations that some doctors received higher rebates on purchases of the company's anti-anemia drug Aranesp. In a statement, Grassley said there were concerns doctors were profiting by getting reimbursements from the government and private insurers that were higher than their actual cost for Aranesp. The drug is currently under scrutiny for safety concerns.